[{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Telacebec","moa":"Cytochrome bc1 complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ Not Applicable"},{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Q901","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Not Applicable"},{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Not Applicable"},{"orgOrder":0,"company":"Qurient","sponsor":"TB Alliance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Telacebec","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qurient \/ Qurient","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ Qurient"}]

Find Clinical Drug Pipeline Developments & Deals by Qurient

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license to develop and commercialize Q203 (telacebec), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis and some NTM infectio...

                          Brand Name : Q203

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 03, 2023

                          Lead Product(s) : Telacebec

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : TB Alliance

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Q702 is an orally available novel Axl/Mer/CSF1R inhibitor and is designed to modulate innate immune components leading to T cell activation. Q702 was also shown to increase antigen presentation in the tumor cells demonstrating dual mode of action.

                          Brand Name : Q702

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 30, 2023

                          Lead Product(s) : Q702,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Q901 is a highly selective CDK7 inhibitor that disrupts tumor cells division cycle progression and blocks DNA damage repair, resulting in tumor cell apoptosis.

                          Brand Name : Q901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 01, 2022

                          Lead Product(s) : Q901

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Clinical data supports continued development of telacebec toward the first universal regimen to overcome tuberculosis regardless of drug resistance status.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 26, 2020

                          Lead Product(s) : Telacebec

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank